Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
Search or
𝛼
SK
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
268
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Primers
New
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Genor Biopharma Holdings
•
17 Sep 2020 01:38
JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure
$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...
Arun George
Follow
530 Views
Share
bearish
•
Shanghai Henlius Biotech
•
18 Sep 2019 15:37
Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China
We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...
Ke Yan, CFA, FRM
Follow
954 Views
Share
bullish
•
Shanghai Henlius Biotech
•
11 Sep 2019 15:34
Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End
Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...
Arun George
Follow
922 Views
Share
bullish
•
Alphamab Co Ltd
•
30 Jul 2019 17:39
Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi
Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...
Ke Yan, CFA, FRM
Follow
638 Views
Share
bearish
•
Jiangsu Hengrui Medicine
•
26 Jun 2019 10:29
China Biotech: Read-Through from Opdivo/Keytruda's Recent Failures (Liver Cancer & Gastric Cancer)
BMS recently reported failed Phase III clinical trial for Opdivo, one of two leading anti-PD-1 (programmed cell death protein 1) monoclonal...
Ke Yan, CFA, FRM
Follow
549 Views
Share
First
Previous
45
46
47
48
49
50
51
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.7
x